A Langley man with a rare type of kidney disease is suing the provincial government, saying it took too long to approve his treatment with a new type of drug.

Paul Chung is suing the province, saying it violated his charter rights to 91裸聊视频渓ife, liberty, and security of the person.91裸聊视频�

Chung was in his first year of university in August of 2017 when he was was diagnosed with atypical hemolytic uremic syndrome (aHUS), which causes blood clots in small blood vessels. That can lead to stroke, heart attack, kidney failure, and death.

In his notice of civil claim, filed with the B.C. Supreme Court registry on July 3, Chung said he is now permanently on kidney dialysis because the provincial government waited until November 2017 to approve his treatment with a new drug, Soliris, 91裸聊视频渁 very expensive drug capable of curing or materially improving his serious blood disorder,91裸聊视频� he sited in the suit.

READ MORE:

After he was turned down, Chung waged a public campaign to convince the government to cover the cost of the new drug treatment.

By the time the province approved a three-month trial, the Chung claim stated, he was suffering from internal bleeding that required surgery.

91裸聊视频淭he decision was too little, too late for the plaintiff [Chung] as Soliris must be administered promptly after diagnosis to be effective.91裸聊视频�

During that time, the lawsuit maintains that other B.C. patients with the same condition recovered because they were given Soliris within four to eight weeks of their first diagnosis.

Chung remains on dialysis, unable to work or attend school, the claim stated.

Denying Chung coverage was, under the circumstances, 91裸聊视频済rossly disproportionate and unreasonable under any public interest calculus,91裸聊视频� the lawsuit stated.

Langley Advance Times has reached out to the provincial government and Chung for comment.

91裸聊视频� Stay tuned for more91裸聊视频�

_________________________________

Is there more to this story?

Email: dan.ferguson@langleyadvancetimes.com

Like us on or follow us on

_________________________________